Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for KURA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 519.02M
March 31, 2026 580.82M
December 31, 2025 667.24M
September 30, 2025 549.66M
June 30, 2025 630.73M
March 31, 2025 658.19M
December 31, 2024 727.40M
September 30, 2024 455.30M
June 30, 2024 491.52M
March 31, 2024 527.12M
December 31, 2023 423.96M
September 30, 2023 452.59M
June 30, 2023 476.98M
March 31, 2023 405.90M
December 31, 2022 437.98M
September 30, 2022 427.78M
June 30, 2022 450.26M
March 31, 2022 480.08M
December 31, 2021 517.96M
September 30, 2021 543.44M
June 30, 2021 567.49M
March 31, 2021 603.87M
December 31, 2020 633.32M
Date Value
September 30, 2020 325.41M
June 30, 2020 338.87M
March 31, 2020 216.94M
December 31, 2019 236.89M
September 30, 2019 250.13M
June 30, 2019 261.41M
March 31, 2019 165.52M
December 31, 2018 178.98M
September 30, 2018 187.42M
June 30, 2018 125.88M
March 31, 2018 138.20M
December 31, 2017 93.14M
September 30, 2017 100.80M
June 30, 2017 53.24M
March 31, 2017 59.15M
December 31, 2016 67.79M
September 30, 2016 74.57M
June 30, 2016 80.09M
March 31, 2016 78.47M
December 31, 2015 85.75M
September 30, 2015 41.23M
June 30, 2015 45.93M
March 31, 2015 53.57M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Inovio Pharmaceuticals, Inc. 36.67M
Fortress Biotech, Inc. 196.58M
Syndax Pharmaceuticals, Inc. 547.86M
Spero Therapeutics, Inc. 50.77M
Gossamer Bio, Inc. 57.03M